Papers using
EP1
antibodies
Papers on
EP1
Discovery of highly potent dual EP2 and EP3 agonists with subtype selectivity.Ohmoto et al., Ōsaka, Japan. In Bioorg Med Chem Lett, Jan 2016
UNASSIGNED: The cyclic carbamate derivatives, 2-{[2-((4S)-4-{(1E,3R)-8-fluoro-3-hydroxy-4,4-dimethyl-1-octenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (5) and 2-{[2-((4S)-4-{(1E,3R)-3-[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (7) were identified as the first potent dual EP2 and EP3 agonists with selectivity against the EP1 and EP4 subtypes.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.Yamamoto et al., Himeji, Japan. In Mol Neurobiol, Oct 2015
PGE2, PGF2α, and TXA2 can contribute to the neurodegeneration via EP1, FP, and TP receptors, respectively, which are coupled with Gq, stimulate phospholipase C and cleave phosphatidylinositol diphosphate to produce inositol triphosphate and diacylglycerol.